The Galapagos share
Galapagos NV (ticker: GLPG) has been listed on Euronext Amsterdam and Brussels since 6 May 2005 and on the Nasdaq Global Select Market since 14 May 2015. Galapagos NV forms part of the Bel20 index (top 20 listed companies) on Euronext Brussels, the AEX Index (top 25 listed companies) on Euronext Amsterdam, and the Nasdaq Biotechnology Index on Nasdaq in New York.
In 2019, the average daily trading volume on Euronext was 453,484 shares and €57.9 million turnover. The daily trading volume on Nasdaq in 2019 was 131,202 ADSs and $18.7 million turnover.
Investor relations activities
We currently have sell-side coverage from >20 analysts and in 2019 we attracted additional sell-side analyst coverage.
Our IR team hosted 8 investor visits of >70 investors to our Mechelen operations, presented at 20 conferences in 2019 in Europe and the U.S. and did several broker-organized and self-organized roadshows throughout the U.S., Europe, and Asia during which we met with >500 investors.
We presented 2018 Full Year, and Q1, Half Year, and Q3 2019 results, our Annual R&D Update, and conference presentations via webcasts.
The main topics of discussion with investors included the filgotinib development programs and commercial strategy, the revised filgotinib agreement with collaboration partner Gilead, our new R&D collaboration agreement with Gilead, our Phase 3 plans with GLPG1690 in IPF patients, our ROCCELLA global Phase 2b trial with collaboration partner Servier in osteoarthritis, and our Toledo program for inflammation.